May 2015 in “Journal of The American Academy of Dermatology” Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.
September 2023 in “Journal of the American Academy of Dermatology”
January 2012 in “heiDOK (Heidelberg University)” Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.
2 citations
,
February 2022 in “Journal of Pharmacy and Pharmacology” Methotrexate-loaded formulations showed promise for psoriasis treatment but need careful evaluation.
15 citations
,
May 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.
9 citations
,
April 2024 in “Advanced Drug Delivery Reviews”
1 citations
,
April 2009 in “Expert Review of Dermatology” The new gel combining calcipotriene and betamethasone is effective and safe for treating scalp psoriasis.
7 citations
,
July 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
March 2018 in “Trends in Immunotherapy” Combining triamcinolone acetonide with immunotherapy can help regrow hair in some alopecia totalis patients.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
1 citations
,
January 2008 in “SKINmed Dermatology for the Clinician” Treatment with prednisolone and dapsone stopped new blisters and partially healed previous ones.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
April 2020 in “Rheumatology” Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
July 2022 in “Journal of Investigative Dermatology”
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
May 2024 in “Frontiers in Medicine” Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
April 2023 in “Journal of Investigative Dermatology” Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.
1 citations
,
August 2019 Anti-Desmocollin 3 antibodies can cause atypical pemphigus symptoms.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.